Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ZEOX | 8-K | neutral | 5/10 | Zeo ScientifiX (ZEOX) entered into a definitive strategic partnership agreement with Pluri Inc. (PLUR) to expand U.S. ma | Oct 26, 2026 |
| GSK | 6-K | bullish | 5/10 | GSK announced positive interim results from the phase II AZUR-1 trial of Jemperli (dostarlimab) monotherapy in MSI-H/dMM | Oct 26, 2026 |
| BNTX | 6-K | bullish | 5/10 | BioNTech and Bristol Myers Squibb reported encouraging Phase 2 data from the ROSETTA Lung-107 trial evaluating pumitamig | Oct 26, 2026 |
| SNY | 6-K | neutral | 2/10 | Sanofi broke ground on a new insulin manufacturing facility in Frankfurt, Germany, with full production of insulin activ | Oct 26, 2026 |
| GSK | 6-K | neutral | 4/10 | GSK announced updated Phase Ib data for its investigational ADC, Mo-Rez, in platinum-resistant ovarian cancer, showing a | Oct 26, 2026 |
| CLYM | 8-K | bullish | 6/10 | Climb Bio announced initial Phase 2 data from its PrisMN trial of budoprutug in primary membranous nephropathy (pMN) at | Oct 26, 2026 |
| BNTX | 6-K | bearish | 5/10 | BioNTech and DualityBio reported topline results from the DYNASTY-Breast02 Phase 3 trial of trastuzumab pamirtecan in HR | Oct 26, 2026 |
| HCM | 6-K | bullish | 6/10 | HUTCHMED reported positive results from two Phase III trials (SAFFRON and SANOVO) of ORPATHYS (savolitinib) plus TAGRISS | Oct 26, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a Form 6-K on October 26, 2026, furnishing links to audio and video recordings of its earnings call he | Oct 26, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a 6-K furnishing the limited review reports from its statutory auditors (Deloitte Haskins & Sells LLP) | Oct 26, 2026 |
| PHAT | 8-K | bearish | 5/10 | Phathom Pharmaceuticals disclosed that the FDA has opened a public docket to solicit comments on legal and regulatory is | Oct 26, 2026 |
| NBTX | 6-K | neutral | 4/10 | Nanobiotix announced final Phase 1 data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant primary cutaneous melanoma, showing | Oct 26, 2026 |
| NBP | 6-K | bullish | 6/10 | NovaBridge Biosciences reported mature Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate | Oct 26, 2026 |
| EIKN | 8-K | neutral | 5/10 | Eikon Therapeutics announced updated Phase 2 data from its TeLuRide-005 trial of EIK1001 (TLR7/8 dual-agonist) in first- | Oct 26, 2026 |
| AVBP | 8-K | bullish | 6/10 | ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted ADC ARR-217 at ESMO 2026, showing a 44.8% ORR a | Oct 26, 2026 |
| PCSA | EFFECT | bearish | 6/10 | The SEC declared effective Processa Pharmaceuticals' S-3 registration statement (File No. 333-299388) on October 23, 202 | Oct 26, 2026 |
| EIKN | PRESS-RELEASE | bullish | 6/10 | Eikon Therapeutics presented updated Phase 2 data for its TLR7/8 agonist EIK1001 in first-line stage 4 NSCLC at ESMO 202 | Oct 26, 2026 |
| BNTX | PRESS-RELEASE | bearish | 6/10 | BioNTech and DualityBiologics announced that the Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan (BNT323/DB-130 | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in fir | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SAFFRON trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in ME | Oct 25, 2026 |
| ORKA | PRESS-RELEASE | neutral | 6/10 | Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in plaque | Oct 25, 2026 |
| AVBP | PRESS-RELEASE | bullish | 5/10 | ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, a CDH17-targeting ADC, in heavily pretreat | Oct 25, 2026 |
| AMRN | PRESS-RELEASE | mixed | 6/10 | Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver metastases | Oct 25, 2026 |
| NBP | PRESS-RELEASE | bullish | 7/10 | NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and 16.9- | Oct 25, 2026 |
| REGN | PRESS-RELEASE | bullish | 5/10 | Regeneron announced longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) in high-risk cuta | Oct 25, 2026 |
| BNTX | PRESS-RELEASE | bullish | 6/10 | BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-107 trial showing pumitamig plus docetaxel achieved a | Oct 25, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced publication of positive Phase 2/3 COMPANION-002 results for tovecimig in advanced biliary | Oct 24, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy a | Oct 24, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | The court denied a joint stipulation to modify the scheduling order and continue the trial in Rapacon v. Abbott Laborato | Oct 23, 2026 |
| HOTH | DEF 14A | bearish | 6/10 | Rocket One Inc. (HOTH) filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval on | Oct 23, 2026 |